Drugs / OB318
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02347228 | Aug 2020 → Nov 2024 | — | Oneness Biotech Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OB318 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02347228 ↗ |
| Route | Oral | “Oral qd, at least 30 minutes before breakfast” NCT02347228 ↗ |